Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• The phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is frequently activated in human cancers, including glioblastoma.
• Understanding the specific roles of PI3K isoforms is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the potential of targeting PI3K isoforms, particularly PI3K p110α, as an anti-tumor strategy in glioblastoma.
• To identify biomarkers predictive of response to PI3K inhibition.

Main Methods:

• Analysis of PI3K isoform expression (p110α, p110β, p110δ) in glioblastoma patient samples.
• Assessment of the correlation between EGFR/PI3K p110α/p-S6 expression and patient survival.
• Inhibition of PI3K isoforms in glioblastoma cell lines and in vivo models to evaluate effects on tumor growth, migration, and pathway activation.

Main Results:

• PI3K p110α was consistently expressed in glioblastoma, while PI3K p110β was rarely detected.
• Expression of the EGFR/PI3K p110α/p-S6 module correlated with shorter patient survival.
• Inhibition of PI3K p110α impaired glioblastoma cell growth, induced tumor regression in vivo, and reduced Akt/mTOR pathway activation.
• Targeting PI3K p110α or PI3K p110β reduced anchorage-independent growth and migratory capacity.
• Inhibition of PI3K p110δ did not yield comparable anti-tumor effects.

Conclusions:

• PI3K p110α is a relevant therapeutic target in a subset of glioblastomas.
• The EGFR/PI3K p110α/p-S6 pathway serves as a potential predictive biomarker for PI3K p110α-targeted therapy.
• Targeting PI3K p110α offers a novel therapeutic approach for glioblastoma with potential for tumor regression and improved patient outcomes.